pravastatin has been researched along with rifampin in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bowornwiriyapan, K; Duangjai, A; Muanprasat, C; Phainuphong, P; Phongpaichit, S; Rukachaisirikul, V; Saithong, S; Sakayaroj, J; Srimaroeng, C | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Backman, JT; Kyrklund, C; Neuvonen, M; Neuvonen, PJ | 1 |
| Agrawal, N; Cox, ML; Kim, RB; Meyer zu Schwabedissen, HE; Obert, LA; Palandra, J; Stock, JL; Tirona, RG; Ware, JA; Zaher, H | 1 |
| Cao, D; Chen, XP; Dai, ZY; Deng, S; Li, YJ; Luo, J; Tang, L; Yin, T | 1 |
| Abe, M; Abe, T; Akiyama, Y; Ishii, A; Ito, S; Mishima, E; Nakagomi-Hagihara, R; Noguchi, N; Onogawa, T; Shibata, E; Shima, H; Shindo, T; Shiwaku, HO; Souma, T; Suzuki, T; Takasawa, S; Takeuchi, Y; Tanemoto, M; Terasaki, T; Toyohara, T; Unno, M; Zheng, G | 1 |
| Bergman, A; Feng, B; Goosen, TC; Lai, Y; Litchfield, J; Varma, MV | 1 |
| Nezasa, K; Ogawa, K; Shimizu, R; Takai, N; Tanaka, Y; Watanabe, A; Watari, R; Yamaguchi, Y | 1 |
| Asaumi, R; Kotani, N; Kusuhara, H; Maeda, K; Nakada, T; Sugiyama, Y; Toshimoto, K; Yoshida, K; Yoshikado, T | 1 |
| Chen, EC; Chen, Y; Choo, EF; Liu, L; Ma, F; Mao, J; Sahasranaman, S; Zhu, R | 1 |
2 review(s) available for pravastatin and rifampin
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for pravastatin and rifampin
| Article | Year |
|---|---|
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plasma; Pravastatin; Rifampin | 2004 |
Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Anticholesteremic Agents; Area Under Curve; China; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Half-Life; Humans; Male; Pravastatin; Rifampin; Single-Blind Method; Tandem Mass Spectrometry; Young Adult | 2009 |
19 other study(ies) available for pravastatin and rifampin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Lovastatin Analogues from the Soil-Derived Fungus Aspergillus sclerotiorum PSU-RSPG178.
Topics: Animals; Aspergillus; Chlorocebus aethiops; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; KB Cells; Lovastatin; Microbial Sensitivity Tests; Molecular Conformation; Mycobacterium scrofulaceum; Nuclear Magnetic Resonance, Biomolecular; Plasmodium falciparum; Soil Microbiology; Thailand; Vero Cells | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin.
Topics: Animals; Female; Gene Targeting; Injections, Intravenous; Liver-Specific Organic Anion Transporter 1; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Organic Anion Transporters, Sodium-Independent; Pravastatin; Rifampin; Substrate Specificity | 2008 |
The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides.
Topics: Adiponectin; Animals; Biological Transport; Cell Line, Tumor; Diabetes Mellitus; Hydroxymethylglutaryl CoA Reductases; Immunohistochemistry; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred Strains; Models, Animal; Organic Anion Transporters, Sodium-Independent; Pancreas; Pravastatin; Rats; Rifampin; Sulfobromophthalein | 2010 |
Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Topics: Adolescent; Adult; Aged; Area Under Curve; Biological Transport; Cells, Cultured; Computer Simulation; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Female; Gemfibrozil; Hepatocytes; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pravastatin; Rifampin; Young Adult | 2012 |
Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction.
Topics: Administration, Intravenous; Administration, Oral; Animals; Antipyrine; Biological Availability; Blood Specimen Collection; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Drug Monitoring; Ibuprofen; Male; Mice, Inbred C57BL; Models, Animal; Organic Anion Transporters; Pravastatin; Reproducibility of Results; Rifampin; Tail; Terfenadine; Triazoles; Veins | 2015 |
Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.
Topics: Antibiotics, Antitubercular; Computer Simulation; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Models, Biological; Organic Anion Transporters; Pravastatin; Quinolines; Rifampin | 2016 |
Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
Topics: Area Under Curve; Cinnamates; Cyclosporine; Drug Interactions; Gemfibrozil; Humans; Indazoles; Liver-Specific Organic Anion Transporter 1; Models, Biological; Pravastatin; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2018 |